Table 1.
ER,PR,HER-2, and Ki-67 expression in patients without/with NAC
| Group | Total | CB+ surgical excision+ | CB+ surgical excision− | CB− surgical excision + | CB− surgical excision− |
|---|---|---|---|---|---|
| Control group | |||||
| ER | 82 | 64 | 0 | 2 | 16 |
| PR | 82 | 54 | 2 | 2 | 24 |
| HER-2 | 82 | 22 | 0 | 2 | 58 |
| Ki-67 | 82 | 49 | 3 | 3 | 27 |
| NAC group | |||||
| ER | 79 | 41 | 9 | 1 | 28 |
| PR | 79 | 33 | 16 | 3 | 27 |
| HER-2 | 79 | 17 | 3 | 1 | 58 |
| Ki-67 | 79 | 9 | 27 | 3 | 40 |
CB, core biopsy. +: positive (HR [hormone receptor] and HER-2 [human epidermal growth factor receptor-2) OR high Ki-67 expression. −: negative (HR and HER-2) OR low Ki-67 expression. ER, estrogen receptor; NAC, neoadjuvant chemotherapy; PR, progesterone receptor.